Literature DB >> 25558779

αvβ6 integrin is required for TGFβ1-mediated matrix metalloproteinase2 expression.

Anindita Dutta1, Jing Li1, Carmine Fedele1, Aejaz Sayeed1, Amrita Singh1, Shelia M Violette2, Thomas D Manes3, Lucia R Languino1.   

Abstract

Transforming growth factor (TGF) β1 activity depends on a complex signalling cascade that controls expression of several genes. Among others, TGFβ1 regulates expression of matrix metalloproteinases (MMPs) through activation of Smads. In the present study, we demonstrate for the first time that the αvβ6 integrin interacts with TGFβ receptor II (TβRII) through the β6 cytoplasmic domain and promotes Smad3 activation in prostate cancer (PrCa) cells. Another related αv integrin, αvβ5, as well as the αvβ6/3 integrin, which contains a chimeric form of β6 with a β3 cytoplasmic domain, do not associate with TβRII and fail to show similar responses. We provide evidence that αvβ6 is required for up-regulation of MMP2 by TGFβ1 through a Smad3-mediated transcriptional programme in PrCa cells. The functional relevance of these results is underscored by the finding that αvβ6 modulates cell migration in an MMP2-dependent manner on an αvβ6-specific ligand, latency-associated peptide (LAP)-TGFβ. Overall, these mechanistic studies establish that expression of a single integrin, αvβ6, is sufficient to promote activation of Smad3, regulation of MMP2 levels and consequent catalytic activity, as well as cell migration. Our study describes a new TGFβ1-αvβ6-MMP2 signalling pathway that, given TGFβ1 pro-metastatic activity, may have profound implications for PrCa therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25558779      PMCID: PMC4363118          DOI: 10.1042/BJ20140698

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  82 in total

1.  Function-blocking integrin alphavbeta6 monoclonal antibodies: distinct ligand-mimetic and nonligand-mimetic classes.

Authors:  Paul H Weinreb; Kenneth J Simon; Paul Rayhorn; William J Yang; Diane R Leone; Brian M Dolinski; Bradley R Pearse; Yukako Yokota; Hisaaki Kawakatsu; Amha Atakilit; Dean Sheppard; Shelia M Violette
Journal:  J Biol Chem       Date:  2004-02-11       Impact factor: 5.157

2.  Integrin-mediated signalling of gelatinase B secretion in colon cancer cells.

Authors:  J Niu; X Gu; J Turton; C Meldrum; E W Howard; M Agrez
Journal:  Biochem Biophys Res Commun       Date:  1998-08-10       Impact factor: 3.575

Review 3.  TGF-beta signaling in cancer--a double-edged sword.

Authors:  R J Akhurst; R Derynck
Journal:  Trends Cell Biol       Date:  2001-11       Impact factor: 20.808

4.  Smad4 protein expression correlates with grade, stage, and DNA ploidy in prostatic adenocarcinomas.

Authors:  Gregory M Sheehan; Bhaskar V S Kallakury; Christine E Sheehan; Hugh A G Fisher; Ronald P Kaufman; Jeffrey S Ross
Journal:  Hum Pathol       Date:  2005-11       Impact factor: 3.466

Review 5.  Roles of TGFbeta in metastasis.

Authors:  David Padua; Joan Massagué
Journal:  Cell Res       Date:  2009-01       Impact factor: 25.617

6.  Overexpression of the alphavbeta6 integrin in endometrial cancer.

Authors:  Jonathan L Hecht; Brian M Dolinski; Humphrey A Gardner; Shelia M Violette; Paul H Weinreb
Journal:  Appl Immunohistochem Mol Morphol       Date:  2008-12

7.  Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression.

Authors:  Lisa G Horvath; Susan M Henshall; James G Kench; Jennifer J Turner; David Golovsky; Phillip C Brenner; Gordon F O'Neill; Raji Kooner; Phillip D Stricker; John J Grygiel; Robert L Sutherland
Journal:  Prostate       Date:  2004-05-15       Impact factor: 4.104

8.  Differential roles of Smad2 and Smad3 in the regulation of TGF-β1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: control by Rac1.

Authors:  Hendrik Ungefroren; Stephanie Groth; Susanne Sebens; Hendrik Lehnert; Frank Gieseler; Fred Fändrich
Journal:  Mol Cancer       Date:  2011-05-30       Impact factor: 27.401

9.  Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.

Authors:  J Akech; J J Wixted; K Bedard; M van der Deen; S Hussain; T A Guise; A J van Wijnen; J L Stein; L R Languino; D C Altieri; J Pratap; E Keller; G S Stein; J B Lian
Journal:  Oncogene       Date:  2009-11-16       Impact factor: 9.867

10.  TGF-beta plays a key role in morphogenesis of the pancreatic islets of Langerhans by controlling the activity of the matrix metalloproteinase MMP-2.

Authors:  F Miralles; T Battelino; P Czernichow; R Scharfmann
Journal:  J Cell Biol       Date:  1998-11-02       Impact factor: 10.539

View more
  15 in total

1.  Exosome-mediated Transfer of αvβ3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype.

Authors:  Amrita Singh; Carmine Fedele; Huimin Lu; Marja T Nevalainen; James H Keen; Lucia R Languino
Journal:  Mol Cancer Res       Date:  2016-07-20       Impact factor: 5.852

2.  Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer.

Authors:  Huimin Lu; Nicholas Bowler; Larry A Harshyne; D Craig Hooper; Shiv Ram Krishn; Senem Kurtoglu; Carmine Fedele; Qin Liu; Hsin-Yao Tang; Andrew V Kossenkov; William K Kelly; Kerith Wang; Rhonda B Kean; Paul H Weinreb; Lei Yu; Anindita Dutta; Paolo Fortina; Adam Ertel; Maria Stanczak; Flemming Forsberg; Dmitry I Gabrilovich; David W Speicher; Dario C Altieri; Lucia R Languino
Journal:  Matrix Biol       Date:  2018-03-09       Impact factor: 11.583

3.  Aberrant TGF-β Signaling Drives Castration-Resistant Prostate Cancer in a Male Mouse Model of Prostate Tumorigenesis.

Authors:  Hong Pu; Diane E Begemann; Natasha Kyprianou
Journal:  Endocrinology       Date:  2017-06-01       Impact factor: 4.736

4.  αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor.

Authors:  Huimin Lu; Tao Wang; Jing Li; Carmine Fedele; Qin Liu; Jianzhong Zhang; Zhong Jiang; Dhanpat Jain; Renato V Iozzo; Shelia M Violette; Paul H Weinreb; Roger J Davis; Daniel Gioeli; Thomas J FitzGerald; Dario C Altieri; Lucia R Languino
Journal:  Cancer Res       Date:  2016-07-22       Impact factor: 12.701

5.  Activation of the TGFβ pathway impairs endothelial to haematopoietic transition.

Authors:  Özge Vargel; Yang Zhang; Kinga Kosim; Kerstin Ganter; Sophia Foehr; Yannicka Mardenborough; Maya Shvartsman; Anton J Enright; Jeroen Krijgsveld; Christophe Lancrin
Journal:  Sci Rep       Date:  2016-02-19       Impact factor: 4.379

Review 6.  Integrins in the Spotlight of Cancer.

Authors:  Daniela Bianconi; Matthias Unseld; Gerald W Prager
Journal:  Int J Mol Sci       Date:  2016-12-06       Impact factor: 5.923

Review 7.  The role of integrins in TGFβ activation in the tumour stroma.

Authors:  Zareen Khan; John F Marshall
Journal:  Cell Tissue Res       Date:  2016-08-12       Impact factor: 5.249

8.  miR-320a functions as a suppressor for gliomas by targeting SND1 and β-catenin, and predicts the prognosis of patients.

Authors:  Huining Li; Lin Yu; Jing Liu; Xiuwu Bian; Cuijuan Shi; Cuiyun Sun; Xuexia Zhou; Yanjun Wen; Dan Hua; Shujun Zhao; Linlin Ren; Tongling An; Wenjun Luo; Qian Wang; Shizhu Yu
Journal:  Oncotarget       Date:  2017-03-21

9.  Inhibition of integrin αVβ6 changes fibril thickness of stromal collagen in experimental carcinomas.

Authors:  P Olof Olsson; Renata Gustafsson; Alexei V Salnikov; Maria Göthe; Kathrin S Zeller; Tomas Friman; Bo Baldetorp; Louise A Koopman; Paul H Weinreb; Shelia M Violette; Sebastian Kalamajski; Nils-Erik Heldin; Kristofer Rubin
Journal:  Cell Commun Signal       Date:  2018-07-02       Impact factor: 5.712

Review 10.  On-Target Anti-TGF-β Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?

Authors:  Adilson Fonseca Teixeira; Peter Ten Dijke; Hong-Jian Zhu
Journal:  Front Cell Dev Biol       Date:  2020-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.